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doi:10.1016/j.ejvs.2011.04.005Abstract Objectives: We have used Ultrasound Guided Foam Sclerotherapy (UGFS) to treat
varicose veins in 2029 limbs since 2006. In 2009 we introduced physiological gas (30% O2 and
70% CO2) for makingfoam with sodium tetradecyl sulphate (Fibrovein, STD Pharmaceutical
Products Ltd, Hereford UK) instead of air. The aim of this study was to compare our early expe-
rience of UFGS using CO2/O2 with our prior experience using air.
Methods: Data were collected in a prospectively maintained database. In this series 470 limbs
were treated with UGFS and followed up at 6 weeks with clinical and duplex ultrasound assess-
ment. The 235 consecutive limbs undergoing UGFS immediately before and the 235 after the
introduction of CO2/O2 were selected for comparison.
Results: The age, gender and CEAP classifications for the two groups were not significantly
different. 73% were primary veins and 70% great saphenous, with no differences between
the groups. Transient neurological events are rare in our experience (0.7%) with only one visual
disturbance occurring in this series. There was a significant reduction in the incidence of skin
staining in the CO2/O2 (7.2% vs 3.3%, p Z 0.02, c
2 test) as compared to the air treated group,
but no difference in the incidence of thrombophlebitis. The total volume of foam injected was
similar in both groups but use of CO2/O2 foam was associated with a significant improvement in
the truncal occlusion rate, from 86% to 91% (p < 0.05, c2 test).
Conclusion: UGFS with CO2/O2 instead of air was associated with a slightly increased saphe-
nous truncal occlusion rate and reduced the incidence of skin staining without increasing
thrombophlebitis in this clinical series. We observed only one transient neurological event in
this series so could not evaluate the effect of CO2/O2 foam in reducing these events.
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Ultrasound guided foam sclerotherapy (UGFS) is increas-
ingly being used as a first line treatment for varicose veins
and there is a number of reports in the literature confirming
its efficacy and safety.1e4 In contrast to endoluminal
thermal or laser ablation, foam sclerotherapy provides
a single technique that can address both the truncal
incompetence and the varicose tributaries. The most
common side effects of foam sclerotherapy are thrombo-
phlebitis and skin pigmentation. There is also the potential
for systemic side effects resulting from foam embolisation.
This is of greatest concern in subjects with a patent
foramen ovale (PFO) and the prevalence of PFO has been
reported to be as high as 10%.5 The most commonly
reported systemic side effects are chest tightness, a dry
cough, dizziness or a transient visual disturbance.6 There
are also reports of stroke7,8 and whilst it is difficult to
confirm causality, experimentally bubbles have been
tracked at the time of UGFS, to the middle cerebral artery
using transcranial Doppler.9,10
The frequency of these side effects is probably related
to the volume of foam injected.6 One strategy to minimise
side effects would be to limit the volume of foam injected
to less than 10 ml as recommended by the European
consensus document.11 In addition there is some data to
suggest that the injection technique is important.12,13 In
one non-randomised retrospective study Hill reported that
for the great saphenous system, leg elevation without
manual sapheno-femoral junction compression reduced the
incidence of echocardiographically detected emboli to the
right heart.
There is some evidence that using carbon dioxide, in place
of air, tomake the foammay also reduce the incidence of side
effects.6,13 In his non-randomised study6 using large volumes
(25 S.D. 12ml) of 1% polidocanol foam,Morrison reported that
the use of CO2 based foam reduced the incidence of systemic
effects from 39% to 11%. Subsequently it has been reported
thatuseofamorephysiological combinationofcarbondioxide
and oxygen may result in a further reduction in these side
effects while still resulting in a good quality foam.14
We began treating varicose veins with ultrasound guided
sclerotherapy as a “first line” modality in 2006 and have
now treated and completed follow-up for 1510 legs. In 2009
we introduced physiological gas to our practise for
producing foam using a mixture of 70% carbon dioxide and
30% oxygen. In this study we aimed to establish if the
introduction of physiological gas for UGFS reduces the
incidence of side effects.
Materials and Methods
This is a prospective study of 470 consecutive patients
treated with UGFS alone for the management of primary or
recurrent varicose veins between 10th August 2008 and
20th January 2010. Data was extracted from a prospectively
maintained database of all patients treated with UGFS. The
database is kept for ongoing clinical audit purposes in
keeping with NICE guidelines. 235 subjects underwent foam
sclerotherapy using physiological gas following its intro-
duction on 6th January 2009 and we have selected the 235consecutive patients treated (using air) immediately prior
to this date for comparison.
Patient population
All patients were given a patient information sheet prior to
their treatment appointment and informed consent was
obtained. As is our routine practise all patients underwent
venous duplex ultrasound examination of the superficial
and deep venous system prior to attending for treatment.
The only absolute exclusion criteria for this study were; age
<18, pregnancy or an inability to comply with compression
hosiery. Unless there is a history of severe migraine with
aura or of a heart murmur we do not routinely screen
patients for a PFO prior to foam sclerotherapy. Neverthe-
less we consider a known PFO or history of deep venous
thrombosis to be relative contraindications to UGFS and no
patients with a history of prior deep vein thrombosis were
treated with UGFS in this series.
Technique
Foam was made by a modification of the Tessari dual
syringe technique15 using a 5 micron filter (B Braun Medical
Ltd, Sheffield, UK) in place of a three-way tap. The physi-
ological gas comprising 70% carbon dioxide and 30% oxygen
was purchased in a pre-mixed cylinder and was drawn up
into a sealed 50 ml syringe in aliquots to facilitate easy
mixing of foam. The gas was mixed in a 3:1 ratio with 3% or
1% sodium tetradecyl sulphate (Fibrovein STD Pharma-
ceutical Products Ltd, UK). We use 3% STS for truncal
varicosities and 1% for any extra -fascial tributaries.
All patients were given a patient information sheet
before attending for treatment, which provided details of
the most frequent systemic side effects of chest tightness,
dizziness and transient visual disturbance, and the poten-
tial complications of thrombophlebitis, skin staining and
deep vein thrombosis. Following administration of 1% lido-
caine local anaesthetic, cannulation was undertaken under
ultrasound guidance. Our primary cannulation technique is
a Seldinger technique, placing a 20G 8 cm long catheter
into the great or small saphenous veins as appropriate, with
butterfly cannulation of any large extra-fascial tributaries.
Following cannulation the limb is elevated prior to injection
of foam and patients actively dorsiflexed and plantarflexed
the ankle to maintain deep venous blood flow. We manually
compressed the sapheno-femoral junction during injection
into the great saphenous vein. Foam migration was moni-
tored with ultrasound during injection of each 3 ml aliquot
and the injection was discontinued when the foam had
reached the junction and good filling was evident resulting
in vasospasm. Upon completion of treatment a class II thigh
length compression stocking was immediately fitted and
worn by the patient for 10 days. A registered nurse moni-
tored the patients during the procedure and patients were
directly questioned regarding any dizziness, transient visual
disturbance or chest tightness and those side effects were
recorded. After treatment patients were asked to walk for
15 min and report back to the nurse prior to discharge.
We aimed to follow-up all patients in this series six
weeks following foam sclerotherapy. Follow-up was
Figure 1 The Proportion of duplex documented occlusions
following UGFS at 8 weeks of follow-up. Complete occlusion
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vascular ultrasound or by the senior author. At follow-up
patients were questioned about any symptomatic
improvement and about side effects. They were also
examined for evidence of any residual varicosities, throm-
bophlebitis or skin staining. The treated veins were exam-
ined using colour duplex ultrasound and the level of
occlusion noted. Venous occlusion was defined as an
incompressible vein in which no flow could be demon-
strated, and in the case of the great saphenous vein
complete occlusion was recorded as occlusion of the
treated segment to within 2 cm of the sapheno-femoral
junction. An incomplete occlusion was also recorded if we
had failed to occlude 85% of the treated venous trunk.was observed in 91.4% of subjects treated with physiological
gas as compared to 86.5% treated with air, p < 0.05. Please
note axis range is from 75% to 100%.Statistical analysis
Statistical analysis was undertaken using PASW (formerly
SPSS, Statistical Package for the Social Sciences). Non-
parametric analysis has been used for comparison between
the two groups (ManneWhitney U test), with Chi squared
contingency table analysis used for frequency analysis.
Data is presented as median (inter-quartile range).Results
The median age of the patients was 58 (47e69) years and
59% were female. 75% of patients treated had primary
varicose veins and in 69% the system treated was the great
saphenous vein. In 81% of patients a Seldinger technique
was used for cannulation with only 19% requiring a butterfly
cannulation alone. 49% of patients were C of CEAP classi-
fication 2, 37% class 4 and 10% classes 5 and 6. The median
volume of foam used in this study was 9 (6e12) ml of 3% STS
and 6 (3e9) ml of 1% and as such the median total volume
was 9 (6e12) ml. There was no significant difference in the
age, sex, classification of veins, system treated or volume
of foam administered between these two groups (Table 1).
No subjects were lost to follow-up in this series, however
whilst we set out to follow-up all subjects at 6 weeks, in
fact the median follow-up interval was 56 days.Table 1 Demographic data describing each group. The descrip
range.
Air n Z 235
Age 55 yrs (20)
Sex 136 female 58%
Classification 180 primary 77%
Venous System
treated
Anterior accessory
saphenous v
21 (9%)
Great saphenous 159 (68%)
Small saphenous 51 (21%)
Cannulation
technique
Seldinger 57%
Butterfly 20%
Combined 23%
Foam Volume
administered (ml)
9 (5e13) mlIn our experience systemic side effects are rare and only
one (0.2%) of these patients experienced transient blurring of
vision. Whilst this event occurred in the air treated group,
there was no statistically significant difference between the
two groups because the incidence was so low. None of the
patients in this series experienced the most commonly
reported side effects of chest tightness, a dry cough or
dizziness.6 Similarly there was only one deep vein thrombosis
amongst this series of 470 patients (0.2%) and whilst this did
occur in the physiological gas treated group the low frequency
of this complication prevented statistical analysis.
When we compared the incidence of local side effects
between the two groups there were significant differences.
There was a reduction in the incidence of skin staining from
7.2% in the air treated to 3.3% in the physiological gas
treated group (p < 0.02). This was not accompanied by
a reduction in the incidence of superficial thrombophle-
bitis, at 3.4% in the air and 5.1% in the physiological gas
treated group (p Z 0.15).
The introduction of physiological gas was also associated
with an increase in the efficacy of treatment (Fig. 1). There
was an increase in the proportion of patients observed to
have a complete truncal occlusion upon follow-up duplex
scanning increasing from 86.5% in the air treated group to
91.4% in the physiological gas treated group (p < 0.05),tors for continuous variables are median with inter-quartile
Physiological gas N Z 235
55 yrs (24) p Z 0.79
142 female 60% p Z 0.76 (c2 test)
171 primary 73% p Z 0.52 (c2 test)
Anterior accessory
saphenous
22 (9%) p Z 0.624 (c2 test)
Great saphenous 166 (71%)
Small saphenous 36 (15%)
Seldinger 59% P Z 0.71 (c2 test)
Butterfly 17%
Combined 24%
9 (2e16) ml p Z 0.22
(ManneWhitney)
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partial occlusions. At present only 6 week follow-up data is
available for this patient cohort. Prior to this series 409
patients treated by UGFS using foam manufactured with air
had completed 1 year of follow-up and the medium-term
occlusion rate was similar to that reported in this series,
with 85% of subjects maintaining complete truncal
occlusion.
Overall 23% of the patients in this series had some
residual varicosities upon clinical examination, however
only 4.9% went on to request further treatment.Discussion
These data confirm that ultrasound guided foam scle-
rotherapy is a safe and effective first line treatment for
varicose veins. We found that the incidence of systemic
side effects is very low, occurring in only 0.2% of patients in
this series. It is therefore not possible to conclude whether
the theoretical benefit of reduced systemic embolisation
witnessed using echocardiography and transcranial
Doppler9,10 is of any clinical significance.
We also report a low incidence of deep vein thrombosis
of only 0.2% associated with ultrasound guided foam scle-
rotherapy, which did not differ between the two groups in
this study. This is lower than that reported in most series1
and whilst this may be a result of our technique and the
relatively low volumes of foam used, it may also reflect the
follow-up interval. In this series subjects were followed up
at a median of 56 days and were only imaged sooner if there
was clinical concern. It is however clear that when deep
vein thromboses occur they are an early event16 and it is
therefore possible that some asymptomatic thromboses
were not identified in this series.
There is a clear discrepancy between the incidence of
systemic side effects reported in this series and those
reported by Morrison. In his first series6 he used polidocanol
foam sclerotherapy as an adjunct to thermal ablation of the
great saphenous vein. He reported that 39% (19/49) of
subjects undergoing UGFS with air based foam experienced
side effects. The use of carbon dioxide in place of air
reduced this incidence to 11% (14/128), but this remains an
order of magnitude greater than the results we report.
Some of this discrepancy may be accounted for by the
rigour with which his study sought side effects, with
a registered nurse monitoring patients for an hour following
the procedure. However, this discrepancy is most likely to
be a result of the injection of large foam volumes (median
of 25 ml (6e57)). Furthermore these were injected into
a reduced capacity superficial venous system following
thermal ablation of the great saphenous vein, resulting in
a greater risk of systemic embolisation.
It was of particular interest that the incidence of
systemic side effects reported6 was volume related, with
very few events occurring below a volume threshold of
16 ml, a finding which supports the European Consensus
limiting the volumes used to less than 10 ml.11
In contrast to Morrison, we report a 91.4% complete
occlusion rate when using a median of only 9 ml of sodium
tetradecyl sulphate foam as a first line intervention for
varicose veins. The lower foam volume used may not onlyreflect the effectiveness of our treatment and our concerns
regarding systemic side effects, but it may also be a func-
tion of our differing treatment goals. Our primary goal is to
achieve symptomatic relief as a result of truncal occlusion,
not necessarily ablation of all cosmetic varicosities.
Morrison has alsomore recently reported the introduction
of physiological gas for UGFS in a series of 100 subjects.14 In
this series using polidocanol foam as an adjunct to thermal
ablation, the foam volumes used were again above the 10 ml
recommended by the European Consenus,11 but of note the
use of physiological gas reduced the incidence of reported
systemic side effects to 3%.
Using smaller but clinically effective doses of physiolog-
ical gas based foam, this study has been unable to demon-
strate any reduction in the systemic side effects associated
withUGFS.Wedo however report a significant increase in the
rate of truncal occlusion and a reduction in the incidence of
skin staining. Despite the potential safety benefits, the
introduction of physiological gas to our practise has not led to
an increase in the volumes of foam administered. As such the
improved occlusion rate witnessed in this series does not
appear to be a volume related effect. The mechanisms for
this benefit are not known, but it may be that the high solu-
bility of the carbon dioxide has a positive effect upon the
interaction between the sclerosant drug and the endothe-
lium. This will require further investigation.
We acknowledge the limitations associated with non-
randomised data, with the inherent introduction of potential
sourcesofbias. Inparticular, onepotential criticismof this data
is that the improvement witnessed may result from an experi-
ence effect. We do not believe this to be the case, as we had
treated more than 1000 legs prior to this series and other than
the introductionofphysiological gasour treatmentprotocolhas
not changed. There was no improvement in the complete
occlusion rate of this cohort of 235 patients air treated patients
(86.5%) when compared with an earlier series of subjects who
have completed twelve months follow-up (85%).
We conclude that the use of physiological gas for ultra-
sound guided foam sclerotherapy increases treatment effi-
cacy andmay also reduce the incidence of skin staining. Given
the potential safety benefits and its small incremental cost
(<1 euro per treatment), we continue to use physiological gas
forultrasoundguided foamsclerotherapyandsuggest that this
is a treatment that warrants further investigation.
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